Navigation Links
ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
Date:10/23/2007

-Lead antibody targeting novel epitope of CD44 found in breast colon, and

prostate cancers-

TORONTO, Oct. 23 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that the lead drug candidate from its CD44 Cancer Stem Cell program has successfully completed its first toxicology study and has shown good efficacy in animal models. ARIUS' program targets a novel epitope of CD44 that has been found in a number of cancer indications including breast, colon, and prostate cancers. Two humanized versions of the CD44 targeting antibody have been generated in preparation for the initiation of human clinical trials in 2008.

"To be effective against cancer, a treatment must eliminate the cancer stems cells that at the heart of the disease that are driving tumor growth and seeding new tumors," said Dr. David Young, President and CEO. "Our CD44 targeting antibody is one of the most advanced drug candidates to target cancer stem cells. CD44 is considered an especially attractive target for anti-tumor drug discovery and development because it has been identified as a cancer stem cell marker in breast, prostate and colon cancers. Having now successfully completed our initial CD44 toxicology study, we look forward to moving our CD44 antibody toward human clinical trials in 2008."

Toxicology Presentation

ARIUS has demonstrated that its antibody targets a novel epitope of CD44 that is present on the majority of human tumors. A dose-ranging pilot toxicology study in non-human primate models demonstrated no dose-limiting toxic effects at doses up to 95 mg/kg. Effects observed in healthy animals were minor and transient.

Additional information can be found at AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics in San Francisco at the following location and times: Abstract B41:
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Streptococcus salivarius
2. Streptococcus salivarius
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... pace of growing computing power could be sustained for ... from the UK,s National Physical Laboratory (NPL) that is ... observed that the density of transistors on an integrated ... time to achieve this, but experts believed that when ...
... OMAHA, Neb., Dec. 9 Transgenomic, Inc.,(OTC Bulletin ... been,awarded an accreditation by the Commission on Laboratory ... on the results of a recent,on-site inspection. Transgenomic ... laboratories nationwide. , Craig Tuttle, CEO ...
... Kingdom and MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - ProMetic ... U.K.-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has signed ... world-leading European Biopharmaceutical company estimated to be worth ... years, with first shipment delivery starting this quarter. ...
Cached Biology Technology:Transgenomic Receives Accreditation From College of American Pathologists 2Transgenomic Receives Accreditation From College of American Pathologists 3ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 2ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 3
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
(Date:4/24/2014)... RICHLAND, Wash. A common plant puts out a welcome ... the mat,s molecular mix. , The study published this week ... reveals new targets during the battle between microbe and ... team showed that the humble and oft-studied plant Arabidopsis ... from a pathogen. It,s as if a hostile army were ...
(Date:4/23/2014)... German . Man ... difference between sexes depends on one single element of the genome: ... two sexual chromosomes are X and Y, whereas women have two ... morphological and physiological differences between males and females. , But this ... the X and Y were identical, until the Y started to ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3
... Nadeau, PhD, of Case Western Reserve University School of ... (NIH) Director,s Pioneer Award. One of 17 ... investigate transgenerational genetic effects, where the biological features and ... depend as much on the genetics of ancestral generations ...
... A 15-year experiment in an outdoor "laboratory" on Ohio ... just as many, if not more, ecological services as will ... been comparing the behavior of two experimental marshes on the ... and another that was left to colonize plant and animal ...
... in Spanish . A beneficial yeast that ... the fungal culprit behind Fusarium head blight ("scab"). U.S. ... isolated an improved variant of the yeast Cryptococcus flavescens ... as a biocontrol agent. In susceptible wheat and ...
Cached Biology News:Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 2Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 3Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 4Flower-dwelling yeast licensed for use against scab disease 2